Prognostic Value of Plasma DPP4 Activity in ST-elevation Myocardial Infarction Patients

Completed

• Conditions: Dipeptidyl Peptidase 4; Coronary Angiography

• Registration Number: NCT03046576
• Lead Sponsor: Chinese PLA General Hospital

Brief Summary

Increased plasma DPP4 activity (DPP4a) could predict both subclinical and new-onset atherosclerosis, and our previous study has found that the DPP4a was significantly lower in MI patients compared with patients having chest pain or unstable angina alone, and DPP4a is associated with no-reflow and major bleeding events in STEMI patients during hospital stay. As no-reflow phenomenon and major bleeding events independently associates with a worse in-hospital and long-term prognosis. One may speculate that the DPP4a is associated with long-term follow-up adverse cardiovascular events in these patients.The hypothesis was tested in this study.

Detailed Description

Not available

Study Timeline

• Study Start: 2013-01-01
• Primary Completion: 2015-09-30
• Study Completion: 2015-09-30
• Study First Submitted: 2017-02-05
• Study First Submitted QC: 2017-02-05
• Study First Posted: 2017-02-08
• Status Verified: 2017-07
• Last Update Submitted: 2017-07-18
• Last Update Posted: 2017-07-21

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 625

Inclusion Criteria

• consecutive patients of acute STEMI come to our department,absent of cardiogenic shock, and survival for at least 24 h after PCI treatment.

Exclusion Criteria

• patients with cancer, and patients who were taking a DPP4 inhibitoror a glucagon-like peptide-1 (GLP-1) analogue

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
major adverse cardiac or cerebrovascular events	The median follow-up was 30 months	including cardiovascular death, non-fatal myocardial infarction, heart failure and stroke

Secondary Outcome Measures

Name	Time	Method
repeated revascularization	The median follow-up was 30 months	defined as repeated PCI or bypass grafting of not only infarct related artery but also non-infarct related artery, driven by ischemic symptoms (stable/unstable angina or re-infarction) or detection of ischemia by non-invasive tests
non-cardiovascular death	The median follow-up was 30 months
stroke	The median follow-up was 30 months	defined using the World Health Organization criteria